Pfizer Limited (PFIZER) - Net Assets
Based on the latest financial reports, Pfizer Limited (PFIZER) has net assets worth Rs42.03 Billion INR (≈ $454.53 Million USD) as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (Rs49.22 Billion ≈ $532.28 Million USD) and total liabilities (Rs7.19 Billion ≈ $77.75 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check strategic asset allocation of Pfizer Limited to assess the company's strategic physical and investment asset allocation.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | Rs42.03 Billion |
| % of Total Assets | 85.39% |
| Annual Growth Rate | 12.73% |
| 5-Year Change | 46.73% |
| 10-Year Change | 73.75% |
| Growth Volatility | 45.63 |
Pfizer Limited - Net Assets Trend (2005–2026)
This chart illustrates how Pfizer Limited's net assets have evolved over time, based on quarterly financial data. For live market cap and overall valuation, see how much is Pfizer Limited worth.
Annual Net Assets for Pfizer Limited (2005–2026)
The table below shows the annual net assets of Pfizer Limited from 2005 to 2026. Also explore Pfizer Limited equity growth rate to track the company's year-over-year net asset growth rate.
| Year | Net Assets | Change |
|---|---|---|
| 2026-03-31 | Rs42.03 Billion ≈ $454.53 Million |
-0.34% |
| 2025-03-31 | Rs42.17 Billion ≈ $456.10 Million |
+17.30% |
| 2024-03-31 | Rs35.96 Billion ≈ $388.84 Million |
+12.10% |
| 2023-03-31 | Rs32.07 Billion ≈ $346.86 Million |
+11.97% |
| 2022-03-31 | Rs28.64 Billion ≈ $309.78 Million |
+19.70% |
| 2021-03-31 | Rs23.93 Billion ≈ $258.80 Million |
-29.52% |
| 2020-03-31 | Rs33.95 Billion ≈ $367.21 Million |
+12.76% |
| 2019-03-31 | Rs30.11 Billion ≈ $325.66 Million |
+12.23% |
| 2018-03-31 | Rs26.83 Billion ≈ $290.18 Million |
+10.93% |
| 2017-03-31 | Rs24.19 Billion ≈ $261.59 Million |
+14.21% |
| 2016-03-31 | Rs21.18 Billion ≈ $229.05 Million |
+7.35% |
| 2015-03-31 | Rs19.73 Billion ≈ $213.37 Million |
+199.66% |
| 2014-03-31 | Rs6.58 Billion ≈ $71.20 Million |
-61.14% |
| 2013-03-31 | Rs16.94 Billion ≈ $183.25 Million |
+29.87% |
| 2012-03-31 | Rs13.05 Billion ≈ $141.10 Million |
+12.14% |
| 2011-03-31 | Rs11.63 Billion ≈ $125.82 Million |
+17.01% |
| 2010-03-31 | Rs9.94 Billion ≈ $107.53 Million |
+10.35% |
| 2009-03-31 | Rs9.01 Billion ≈ $97.45 Million |
+38.69% |
| 2008-03-31 | Rs6.50 Billion ≈ $70.26 Million |
+47.75% |
| 2007-03-31 | Rs4.40 Billion ≈ $47.56 Million |
+16.97% |
| 2006-03-31 | Rs3.76 Billion ≈ $40.66 Million |
+10.73% |
| 2005-03-31 | Rs3.40 Billion ≈ $36.72 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Pfizer Limited's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 1147.7% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (March 2026)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | Rs24.03 Billion | 57.19% |
| Common Stock | Rs457.50 Million | 1.09% |
| Other Comprehensive Income | Rs4.33 Billion | 10.30% |
| Other Components | Rs13.21 Billion | 31.42% |
| Total Equity | Rs42.03 Billion | 100.00% |
Pfizer Limited Competitors by Market Cap
The table below lists competitors of Pfizer Limited ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Atea ASA
OL:ATEA
|
$1.98 Billion |
|
Eris Lifesciences Limited
NSE:ERIS
|
$1.98 Billion |
|
IBF Financial Holdings Co Ltd
TW:2889
|
$1.98 Billion |
|
AVI LTD (UNSP.ADR)/5
F:IZ60
|
$1.98 Billion |
|
L1 Group Limited
AU:L1G
|
$1.98 Billion |
|
Anywhere Real Estate Inc
NYSE:HOUS
|
$1.98 Billion |
|
Jilin OLED Material Tech Co Ltd
SHG:688378
|
$1.98 Billion |
|
Acuren Corporation
NYSE:TIC
|
$1.98 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Pfizer Limited's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2025 to 2026, total equity changed from 42,174,100,000 to 42,029,000,000, a change of -145,100,000 (-0.3%).
- Net income of 7,224,300,000 contributed positively to equity growth.
- Dividend payments of 7,516,400,000 reduced retained earnings.
- Other comprehensive income increased equity by 178,999,999.
Equity Change Factors (2025 to 2026)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | Rs7.22 Billion | +17.19% |
| Dividends Paid | Rs7.52 Billion | -17.88% |
| Other Comprehensive Income | Rs179.00 Million | +0.43% |
| Other Changes | Rs-32.00 Million | -0.08% |
| Total Change | Rs- | -0.34% |
Book Value vs Market Value Analysis
This analysis compares Pfizer Limited's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 4.36x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 35.18x to 4.36x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2005-03-31 | Rs113.78 | Rs4002.40 | x |
| 2006-03-31 | Rs125.99 | Rs4002.40 | x |
| 2007-03-31 | Rs135.96 | Rs4002.40 | x |
| 2008-03-31 | Rs217.73 | Rs4002.40 | x |
| 2009-03-31 | Rs301.96 | Rs4002.40 | x |
| 2010-03-31 | Rs333.21 | Rs4002.40 | x |
| 2011-03-31 | Rs389.88 | Rs4002.40 | x |
| 2012-03-31 | Rs437.21 | Rs4002.40 | x |
| 2013-03-31 | Rs567.81 | Rs4002.40 | x |
| 2014-03-31 | Rs143.92 | Rs4002.40 | x |
| 2015-03-31 | Rs431.26 | Rs4002.40 | x |
| 2016-03-31 | Rs462.95 | Rs4002.40 | x |
| 2017-03-31 | Rs528.72 | Rs4002.40 | x |
| 2018-03-31 | Rs586.49 | Rs4002.40 | x |
| 2019-03-31 | Rs658.22 | Rs4002.40 | x |
| 2020-03-31 | Rs742.18 | Rs4002.40 | x |
| 2021-03-31 | Rs523.07 | Rs4002.40 | x |
| 2022-03-31 | Rs626.10 | Rs4002.40 | x |
| 2023-03-31 | Rs701.08 | Rs4002.40 | x |
| 2024-03-31 | Rs785.94 | Rs4002.40 | x |
| 2025-03-31 | Rs921.88 | Rs4002.40 | x |
| 2026-03-31 | Rs918.73 | Rs4002.40 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Pfizer Limited utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 17.19%
- The company demonstrates strong efficiency in generating profits from shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 28.67%
- • Asset Turnover: 0.51x
- • Equity Multiplier: 1.17x
- Recent ROE (17.19%) is below the historical average (18.74%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2005 | 13.13% | 7.52% | 1.14x | 1.54x | Rs106.34 Million |
| 2006 | 18.81% | 11.23% | 1.09x | 1.53x | Rs331.37 Million |
| 2007 | 26.21% | 15.35% | 1.07x | 1.59x | Rs657.62 Million |
| 2008 | 52.33% | 48.71% | 0.80x | 1.34x | Rs2.75 Billion |
| 2009 | 33.25% | 43.95% | 0.62x | 1.22x | Rs2.09 Billion |
| 2010 | 13.77% | 17.72% | 0.64x | 1.21x | Rs374.50 Million |
| 2011 | 14.52% | 19.25% | 0.63x | 1.19x | Rs525.32 Million |
| 2012 | 12.99% | 15.51% | 0.69x | 1.21x | Rs389.73 Million |
| 2013 | 29.70% | 53.08% | 0.46x | 1.22x | Rs3.34 Billion |
| 2014 | 10.60% | 3.77% | 2.00x | 1.40x | Rs39.78 Million |
| 2015 | 3.54% | 3.77% | 0.71x | 1.32x | Rs-1.27 Billion |
| 2016 | 14.40% | 15.16% | 0.69x | 1.38x | Rs931.82 Million |
| 2017 | 13.92% | 17.13% | 0.60x | 1.35x | Rs948.92 Million |
| 2018 | 13.42% | 18.29% | 0.53x | 1.38x | Rs917.50 Million |
| 2019 | 14.25% | 20.61% | 0.53x | 1.31x | Rs1.28 Billion |
| 2020 | 14.99% | 23.66% | 0.49x | 1.30x | Rs1.70 Billion |
| 2021 | 20.79% | 22.21% | 0.69x | 1.36x | Rs2.58 Billion |
| 2022 | 21.39% | 23.46% | 0.67x | 1.36x | Rs3.26 Billion |
| 2023 | 19.45% | 25.73% | 0.61x | 1.25x | Rs3.03 Billion |
| 2024 | 15.33% | 25.14% | 0.52x | 1.18x | Rs1.92 Billion |
| 2025 | 18.20% | 33.65% | 0.46x | 1.16x | Rs3.46 Billion |
| 2026 | 17.19% | 28.67% | 0.51x | 1.17x | Rs3.02 Billion |
Industry Comparison
This section compares Pfizer Limited's net assets metrics with peer companies in the Drug Manufacturers - General industry.
Industry Context
- Industry: Drug Manufacturers - General
- Average net assets among peers: $8,340,337,472
- Average return on equity (ROE) among peers: 25.44%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Pfizer Limited (PFIZER) | Rs42.03 Billion | 13.13% | 0.17x | $1.98 Billion |
| GlaxoSmithKline Pharmaceuticals Limited (GLAXO) | $17.41 Billion | 35.07% | 0.91x | $5.20 Billion |
| NGL Fine-Chem Limited (NGLFINE) | $2.23 Billion | 9.21% | 0.29x | $184.95 Million |
| Sanofi India Limited (SANOFI) | $16.27 Billion | 19.76% | 0.48x | $768.97 Million |
| SANOFI CONS HEALTHC IND L (SANOFICONR) | $3.84 Billion | 62.53% | 0.42x | $1.00 Billion |
| SENORES PHARMACEUTICALS L (SENORES) | $9.65 Billion | 11.96% | 0.66x | $698.57 Million |
| TTK Healthcare Limited (TTKHLTCARE) | $646.73 Million | 14.11% | 1.39x | $160.45 Million |
About Pfizer Limited
Pfizer Limited engages in manufacturing, marketing, trading, and distribution of pharmaceutical products in India and internationally. It offers therapy area and products, such as vaccines, injectables and anti-infectives, inflammation and immunology, and internal medicine for cardiovascular care, oncology, respiratory, multivitamins and multimineral, neuroscience, women's health, gastroenterolog… Read more